A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Polyvalent Env (A,B,C,A/E) / Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV-1 Vaccines (PDPHV-201401) as a Prime-boost Regimen or Co-administered in Repeated Doses, in Healthy, HIV-1-Uninfected Adult Participants
Latest Information Update: 27 Apr 2022
At a glance
- Drugs PDPHV 201401 (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 06 Jul 2021 New trial record